Timothy Bi

Timothy Bi

Auto-generated profile, based on publicly available information

Timothy Bi

Fred Hutchinson Cancer Center, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DSDylan Shea
Dylan Shea
CHCheng-Chieh Hsu
Cheng-Chieh Hsu
TBTimothy M. Bi
Timothy M. Bi
NPNatasha Paranjapye
Natasha Paranjapye
MCMatthew Childers
Matthew Childers
VDValerie Daggett
Valerie Daggett
Alzheimer’s disease (AD) is characterized by the deposition of β-sheet–rich, insoluble amyloid β-peptide (Aβ) plaques; however, plaque burden is not correlated with cognitive impairment in AD patients; instead, it is correlated with the presence of toxic soluble oligomers. Here, we show, by a variety of different techniques, that these Aβ oligomers adopt a nonstandard secondary structure, termed “α-sheet.” These oligomers form in the lag phase of aggregation, when Aβ-associated cytotoxicity peaks, en route to forming nontoxic β-sheet fibrils. De novo-designed α-sheet peptides specifically and tightly bind the toxic oligomers over monomeric and fibrillar forms of Aβ, leading to inhibition of aggregation in vitro and neurotoxicity in neuroblastoma cells. Based on this specific binding, a soluble oligomer-binding assay (SOBA) was developed as an indirect probe of α-sheet content. Combined SOBA and toxicity experiments demonstrate a strong correlation between α-sheet content and toxicity. The designed α-sheet peptides are also active in vivo where they inhibit Aβ-induced paralysis in a transgenic AβCaenorhabditis elegansmodel and specifically target and clear soluble, toxic oligomers in a transgenic APPsw mouse model. The α-sheet hypothesis has profound implications for further understanding the mechanism behind AD pathogenesis.

1 April 2020 in Cell Reports
Verified
Journal Article
Open access
FMFlorian Mair
Florian Mair
JEJami R. Erickson
Jami R. Erickson
VVValentin Voillet
Valentin Voillet
YSYannick Simoni
Yannick Simoni
TBTimothy Bi
Timothy Bi
MPMartin Prlic
Martin Prlic
High-throughput single-cell RNA sequencing (scRNA-seq) has become a frequently used tool to assess immune cell heterogeneity. Recently, the combined measurement of RNA and protein expression was developed, commonly known as cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq). Acquisition of protein expression data along with transcriptome data resolves some of the limitations inherent to only assessing transcripts but also nearly doubles the sequencing read depth required per single cell. Furthermore, there is still a paucity of analysis tools tovisualize combined transcript-protein datasets. Here, we describe a targeted transcriptomics approach that combines an analysis of over 400 genes with simultaneous measurement of over 40 proteins on 2 × 104 cells in a single experiment. This targeted approach requires only about one-tenth of the read depth compared to a whole-transcriptome approach while retaining high sensitivity for low abundance transcripts. To analyze these multi-omic datasets, we adapted one-dimensional soli expression by nonlinear stochastic embedding (One-SENSE) for intuitive visualization of protein-transcript relationships on a single-cell level.

30 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
AYAlbert C. Yeh
Albert C. Yeh
AVAntiopi Varelias
Antiopi Varelias
ARAnupama Reddy
Anupama Reddy
SBSierra M. Barone
Sierra M. Barone
SOStuart D. Olver
Stuart D. Olver
GHGeoffrey R. Hill
Geoffrey R. Hill
Donor and recipient cytomegalovirus (CMV) serostatus correlate with transplant-related mortality that is associated with reduced survival following allogeneic stem cell transplant (SCT). Prior epidemiologic studies have suggested that CMV seronegative recipients (R–) receiving a CMV-seropositive graft (D+) experience inferior outcomes compared with other serostatus combinations, an observation that appears independent of viral reactivation. We therefore investigated the hypothesis that prior donor CMV exposure irreversibly modifies immunologic function after SCT. We identified a CD4+/CD57+/CD27– T-cell subset that was differentially expressed between D+ and D– transplants and validated results with 120 patient samples. This T-cell subset represents an average of 2.9% (D–/R–), 18% (D–/R+), 12% (D+/R–), and 19.6% (D+/R+) (P < .0001) of the total CD4+ T-cell compartment and stably persists for at least several years post-SCT. Even in the absence of CMV reactivation post-SCT, D+/R– transplants displayed a significant enrichment of these cells compared with D–/R– transplants (P = .0078). These are effector memory cells (CCR7–/CD45RA+/−) that express T-bet, Eomesodermin, granzyme B, secrete Th1 cytokines, and are enriched in CMV-specific T cells. These cells are associated with decreased T-cell receptor diversity (P < .0001) and reduced proportions of major histocompatibility class (MHC) II expressing classical monocytes (P < .0001), myeloid (P = .024), and plasmacytoid dendritic cells (P = .0014). These data describe a highly expanded CD4+ T-cell population and putative mechanisms by which prior donor or recipient CMV exposure may create a lasting immunologic imprint following SCT, providing a rationale for using D– grafts for R– transplant recipients.

1 September 2018
Verified
Journal Article
Open access
TBTimothy M. Bi
Timothy M. Bi
VDValerie Daggett
Valerie Daggett
A major barrier to developing effective treatments and diagnostics for amyloid diseases is the inability of traditional protein structure characterization methods to elucidate the structure of the toxic oligomers that form during amyloidogenesis. Some years ago, our lab "discovered" a novel protein secondary structure in molecular dynamics simulations of multiple unrelated amyloid proteins, which we call alpha-sheet. We hypothesize that alpha-sheet plays an important role in amyloid aggregation and oligomer toxicity. De novo monomeric alpha-sheet peptides designed to be complementary to the structure observed in simulations inhibit amyloid aggregation and toxicity and specifically bind to the toxic oligomeric species in a variety of unrelated mammalian and bacterial amyloid systems associated with a range of diseases. Furthermore, spectroscopic analysis of alpha-sheet structure, including nuclear magnetic resonance (NMR dagger), circular dichroism (CD), and Fourier-transform infrared spectroscopy (FTIR), correspond well to values predicted for alpha-sheet. These alpha-sheet designs are now being tested for their ability to detect and neutralize toxic oligomers in animals and in patient samples, demonstrating the potential of this nonstandard secondary structure as a target for therapeutic and diagnostic agents for amyloid diseases.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
HRHeeju Ryu
Heeju Ryu
TBTimothy Bi
Timothy Bi
KSKorok Sarkar
Korok Sarkar
CCCandice Church
Candice Church
NRNirasha Ramchurren
Nirasha Ramchurren
ENEvan Newell
Evan Newell
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer often associated with clonal integration of Merkel cell polyomavirus (MCPyV) and expression of T antigen oncoproteins in 80% of cases with the remainder of cases caused by UV mutations.1,2 PD-1 blockade is effective in treating both etiologies of MCC patients, however, only ~60% of patients respond.3 MCPyV-specific T cells are implicated in immunotherapeutic responses4, yet further qualitative and quantitative analysis of those cells among responders and non-responders is needed. Methods We analyzed MCPyV-specific T cells in blood from responders (CR, n=13) and non-responders (n=6 for partial responses, PR; n=5 for stable and progressive disease, SD/PD) before, during and after anti-PD-1 immunotherapy (from trial NCT02267603) using a mass cytometry (CyTOF)-based multiplexed peptide-MHC tetramer staining approach. This allowed us to simultaneously assess 76 MCPyV epitopes and 34 control epitopes derived from viruses such as CMV, EBV, Flu, and HSV, in parallel with 34 cellular phenotyping markers of differentiation, trafficking, and exhaustion. We also performed deep TCR sequencing of sorted T cell populations from the blood samples to track T cell clonotypes between the periphery and tumor. Results Combinatorial tetramer staining with CyTOF allowed us to detect T cells specific for 11 previously reported and 5 novel MCPyV-specific epitopes. Frequencies of MCPyV-specific cells were higher in patients with CR (mean = 0.103% of CD8+ T cells) than those with PR (mean = 0.021%; P=0.007) and SD/PD (mean = 0.003%; P<0.0001) at the baseline, and decreased over the course of immunotherapy in patients with CR. Strikingly, the phenotypes of MCPyV-specific CD8+ T cells were enriched for an activated/exhausted (CD71+PD-1+CD39+) phenotype. Those cells also highly expressed cutaneous lymphocyte-associated antigen (CLA), a marker of skin trafficking, and CD103, a marker of tissue-recirculating cells. Informed by these phenotypes, high-dimensional profiling of bulk CD8+ T cells revealed correlations of the frequencies of CD39+ cells co-expressing CLA or CD103 with both the baseline tumor burden and magnitude of clinical outcome. TCR sequencing was used to assess clonal sharing between tumor infiltrating T cells and these subpopulations of CD8+ T cells from blood. Conclusions Although these findings need to be confirmed in an independent cohort, our high-dimensional analysis and immune profiling of MCC patients suggest that MCPyV-specific cells and CD39+ cells co-expressing CLA or CD103 in blood are enriched for tumor-reactive TCRs and potentially useful as blood-based biomarkers of response to immunotherapy or for novel cellular therapeutic strategies. Trial Registration ClinicalTrials.gov NCT02267603 References Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319(5866):1096–100. Goh G., Walradt T., Markarov V., Blom A., Riaz N., Doumani R., Stafstrom K., Moshiri A., Yelistratova L., Levinsohn J., Chan T. A., Nghiem P., Lifton R. P., Choi J. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 2016;7:3403–3415. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 2016;374(26):2542–52. Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, Jing L, Shinohara M, Gavvovidis I, Willimsky G, McIntosh M, Blankenstein T, Koelle DM, Nghiem P. Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res 2017;5(2):137–147. Ethics Approval The samples were provided by Cancer Immunotherapy Trails Network (trial registration: ClinicalTrials.gov NCT02267603) and the analysis was performed according to the IRB file/approval number IR File #10686.